Registry data analysis of hematopoietic stem cell transplantation on systemic chronic active Epstein–Barr virus infection patients in Japan
Authors:
- Masahide YamamotoMYMasahide Yamamoto
- Yasushi OnishiYOYasushi Onishi
- Yoji SasaharaYSYoji Sasahara
- Hideki SanoHSHideki Sano
- Masayoshi MasukoMMMasayoshi Masuko
- Hirohisa NakamaeHNHirohisa Nakamae
- Ken‐Ichi MatsuokaKMKen‐Ichi Matsuoka
- Takahide AraTATakahide Ara
- Kana WashioKWKana Washio
- Makoto OnizukaMOMakoto Onizuka
- Kenichiro WatanabeKWKenichiro Watanabe
- 30 March 2022
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 97 (6) , 780-790
Abstract
The effects of allogeneic hematopoietic stem cell transplantation (allo‐HSCT) on systemic chronic active Epstein–Barr virus infection (sCAEBV) are yet to be analyzed in a large number of patients. Using the Japanese registry database, Transplant Registry Unification Management Program, we investigated the outcomes of 102 sCAEBV patients who underwent allo‐HSCT. The median age at HSCT was 21 years, and the three‐year overall survival (3‐year OS) rate was 72.5%. Of the 90 patients whose viral load after allo‐HSCT was evaluated, 56 (62.2%) achieved a virological complete response, defined by the complete resolution of disease activity with a significant decrease in EBV‐DNA in peripheral blood. The multivariate Cox proportional hazard model indicated that advanced age, in adolescents and young adults (AYA) (age, 15–39) and adults (age, ≥40 years) was a risk factor of poor OS. The hazard ratios (HRs) of the AYA and adult groups were 10.87 (95% confidence interval [CI]: 1.98–59.56, p = .006) and 15.93 (95% CI: 2.45–103.8, p = .004), respectively. Disease activity (HR 5.74), elevated soluble IL‐2 receptor (sIL‐2R) (≥ median, 691 U/mL) at HSCT (HR 6.93), and conditioning without radiotherapy (HR 3.53) were also independently associated with poor survival. Notably, 79% of radiotherapy doses were less than 6 Gy. Regardless of the presence of hemophagocytic lymphohistiocytosis, the group with a high sIL‐2R level (≥2000 U/mL) showed a poorer prognosis. Although allo‐HSCT is the only curative therapy for sCAEBV, treatment strategies need to be improved for high‐risk patients, especially those with high levels of sIL‐2R.Keywords
Funding Information
- Japan Agency for Medical Research and Development (18ek0109334h0001, 19ek0109334h0002, 20ek0109334h0003, 21ek0109334h0004)
This publication has 26 references indexed in Scilit:
- Investigation of the freely available easy-to-use software ‘EZR’ for medical statisticsBone Marrow Transplantation, 2012
- EBV-associated T/NK–cell lymphoproliferative diseases in nonimmunocompromised hosts: prospective analysis of 108 casesBlood, 2012
- Excellent outcome of allogeneic hematopoietic SCT with reduced-intensity conditioning for the treatment of chronic active EBV infectionBone Marrow Transplantation, 2010
- Defining the Intensity of Conditioning Regimens: Working DefinitionsTransplantation and Cellular Therapy, 2009
- Macrophage activation syndrome: Serological markers and treatment with anti-thymocyte globulinClinical Immunology, 2009
- Reduced-Intensity Conditioning Regimen Workshop: Defining the Dose Spectrum. Report of a Workshop Convened by the Center for International Blood and Marrow Transplant ResearchTransplantation and Cellular Therapy, 2009
- Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP systemInternational Journal of Hematology, 2007
- HLH‐2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosisPediatric Blood & Cancer, 2006
- Proposed guidelines for diagnosing chronic active Epstein‐Barr virus infectionAmerican Journal of Hematology, 2005
- The Chronic Mononucleosis SyndromeThe Journal of Infectious Diseases, 1988